PACSCAN: Chest CT-scan for the Diagnosis of Community-acquired Pneumonia

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Completed
CT.gov ID
NCT01574066
Collaborator
(none)
339
4
1
20
84.8
4.2

Study Details

Study Description

Brief Summary

Primary objective : to estimate impact of CT-scan on diagnostic for emergency department (ED) patients with suspected Community-acquired Pneumonia (CAP).

Secondary objective: to estimate impact of CT-scan on treatment (antimicrobial therapy) and site of care for ED patients with suspected CAP.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Chest CT-scan
N/A

Detailed Description

Rational: Community-acquired pneumonia (CAP) is a frequent infectious disorder in patients visiting the ED. CAP is responsible for high morbidity and associated-mortality is increasing in Western countries. CAP corresponds to invasion of the lung by pathogens. Diagnosis depends on clinical and X-ray assessment. However, these signs and symptoms are poorly specific and are often lacking. As prognosis depends on precocious and fitted antimicrobial treatment, making CAP diagnosis in a short time span (4-8 hours) is mandatory. Preliminary studies suggest that chest CT-scan could over-performed X-ray for diagnosis of CAP. Consensus conferences suggest the use of CT-scan in patients with uncertain diagnosis and unusual presentation and outcome. Because CT-scan is currently easily available, its use in a first intent is questionable for ED patients with suspected CAP.

Primary objective: to estimate impact of CT-scan on diagnostic for ED patients with suspected CAP.

Secondary objective: to estimate impact of CT-scan on treatment (antimicrobial therapy) and site of care for ED patients with suspected CAP.

Prospective multicenter study to measure chest CT-scan impact. 350 patients visiting the ED of 4 inner tertiary teaching hospitals in Paris, France, with suspected CAP.

Management: Patients will be managed according to current guidelines, including conventional chest X-ray.

Evaluation criteria. Attending ED physicians will implement pre- and post-test proforma for diagnosis (CAP) level of certainty, treatment (antimicrobial agents), site of care, before and after chest CT-scan. Comparison of ED physician's answers before/after CT-scan. Patients will be followed until day 28. An adjudication committee (1 pneumologist, 1 infectiologist, 1 radiologist)will review patients' data for gold standard diagnosis.

Statistical considerations: The investigators hypothesize that chest CT-scan wil modify diagnosis certainty in 20%. This implies that 300 participants should be enrolled to allow assessment of changes in 15 % et 25 %. Undue changes will be calculated a posteriori when diagnosis gold standard will be established by adjudication committee.

Anticipated results: Chest CT-scan should improve diagnosis certainty, treatment and site-of-care in patients visiting the ED with suspected CAP. If this is observed in at least 20%, the investigators will measure impact of chest CT-scan in a prospective randomized interventional study.

Study Design

Study Type:
Interventional
Actual Enrollment :
339 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Chest CT-scan for the Diagnosis of Community-acquired Pneumonia in Patients Visiting the Emergency Department
Study Start Date :
Nov 1, 2011
Actual Primary Completion Date :
Dec 1, 2012
Actual Study Completion Date :
Jul 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Experimental: Chest CT-scan

Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan

Procedure: Chest CT-scan
Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan

Outcome Measures

Primary Outcome Measures

  1. Chest CT-scan [in 28 days]

    Percentage of diagnoses modified by chest CT-scan.

Secondary Outcome Measures

  1. Treatments changes [in 28 days]

    Percentage of treatments changes (antimicrobial therapy) modified by chest CT-scan

  2. Changes of site-of-care [in 28 days]

    Percentage of site-of-care (admission/non admission) modified by chest CT-scan

  3. Identification of viral and bacterial agents [at day of inclusion (day 1)]

    Identification of viral and bacterial agents from nasal and pharyngeal swabs

  4. Markers of infection in the blood [at day of inclusion (day 1)]

    Determination of markers of infection in the blood

  5. Markers of infection and markers of inflammation in urine [at day of inclusion (day 1)]

    Determination of markers of infection and of inflammation in urine

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient above 18 years of age

  • Patient with a presumptive diagnosis of CAP according to attending ED physician

  • Patient experiencing at least one systemic sign (T°>38°C or < 36°C, HR>90/min, RR>20/min)

  • Patient experiencing one respiratory sign (cough, lateral chest pain, localized crackles, dyspnea) that recently appeared

  • Patient with a prior medical examination, the results have been or will be communicated

  • Patient gave written informed consent or in cases of emergency parent/ support person who gave written informed consent if he/she is present on the day of inclusion

Exclusion Criteria:
  • Pregnancy

  • Patient with shock

  • Patient with respiratory distress and immune suppression

  • Patient with other criteria for immediate ICU referral to ICU

  • Patient with living conditions making it impossible to follow 28 days

  • Patient not affiliated with a social security system

Contacts and Locations

Locations

Site City State Country Postal Code
1 La Pitié Salpêtrière Hospital Paris France 75013
2 Cochin Hospital Paris France 75014
3 Bichat Hospital Paris France 75018
4 Tenon Hospital Paris France 75020

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

  • Principal Investigator: Yann-Erick Claessens, MD, PhD, Cochin Hospital, Paris, France

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01574066
Other Study ID Numbers:
  • AOM10014
  • P100121
First Posted:
Apr 10, 2012
Last Update Posted:
Aug 2, 2013
Last Verified:
Jul 1, 2013
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2013